Ozempic Gallbladder Disease Causation: Does Ozempic Cause Gallbladder Disease?

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

Legacy Context: From General Health Information to Occupational Exposure

Cambrex Corporation’s historical communications, as reflected in its 1997 financial disclosures and merger announcements, consistently framed its operations within a general health and science information context. These releases emphasized corporate growth, product category performance, and strategic acquisitions, such as the BioWhittaker agreement, without delving into specific health outcomes or exposure risks. This legacy heritage positioned Cambrex as a supplier of fine chemicals and biological products, serving pharmaceutical and biotechnology clients under broad regulatory and safety standards. Transitioning from this general health context to a more focused occupational exposure concern requires a pivot toward the downstream implications of mass production. As Cambrex’s manufacturing processes scaled to meet demand for active pharmaceutical ingredients, the potential for worker exposure to these compounds became a relevant consideration. In particular, the production of glucagon-like peptide-1 receptor agonists, such as semaglutide (marketed as Ozempic), introduces a scenario where occupational contact may occur during synthesis, formulation, or packaging. This shift in perspective moves from corporate financial health and product safety assurances to a targeted inquiry: whether such exposure in a mass production setting could be associated with gallbladder disease risk. The following discussion examines this transition, focusing on exposure pathways rather than mechanistic claims.

Bridge Transition: From Manufacturing to Clinical Evidence

While occupational exposure during mass production is a plausible concern, the primary evidence linking Ozempic (semaglutide) to gallbladder disease comes from clinical and postmarketing data. The drug's prescribing information includes a specific warning for acute gallbladder disease, covering conditions such as cholelithiasis (gallstones) and cholecystitis (inflammation of the gallbladder) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). This warning is based on reports from GLP-1 receptor agonist trials and postmarketing experience (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98). Understanding this clinical context is essential for evaluating potential risks in both therapeutic and occupational settings.

Clinical Evidence and Risk Context

The relationship between Ozempic (semaglutide) and gallbladder disease is documented in the drug's prescribing information and postmarketing surveillance data. Ozempic is a glucagon-like peptide 1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus and to reduce the risk of major adverse cardiovascular events in those with established cardiovascular disease (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The drug's label includes a specific warning for acute gallbladder disease, which covers conditions such as cholelithiasis (gallstones) and cholecystitis (inflammation of the gallbladder) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). This warning is based on reports from GLP-1 receptor agonist trials and postmarketing experience (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98). Clinical presentation of gallbladder disease typically includes symptoms such as right upper quadrant abdominal pain, nausea, vomiting, and fever, with diagnosis confirmed through imaging studies like ultrasound. The prescribing information advises that if cholelithiasis or cholecystitis are suspected, gallbladder studies are indicated (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98). In placebo-controlled trials for glycemic control, cholelithiasis was reported in 1% of patients treated with semaglutide tablets at a dose of 7 mg once daily (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98). This incidence rate provides a quantitative anchor for the risk, though it is important to note that the absolute risk remains low. Mechanistic pathways linking Ozempic to gallbladder disease are not fully elucidated in the provided evidence, but several hypotheses exist. GLP-1 receptor agonists like semaglutide slow gastric emptying and alter gastrointestinal motility, which may affect bile secretion and gallbladder emptying. Reduced gallbladder motility can lead to bile stasis, a known risk factor for gallstone formation. Additionally, weight loss associated with Ozempic use may increase the risk of cholelithiasis, as rapid weight reduction can alter bile composition and promote stone formation. The label notes that severe gastrointestinal adverse reactions have been associated with Ozempic use, and the drug is not recommended in patients with severe gastroparesis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98), which may indirectly relate to gallbladder function. Regarding the adequacy of warnings, the prescribing information includes a dedicated section (5.8) on acute gallbladder disease, which is a standard regulatory requirement for drugs with such risks. The warning advises healthcare providers to suspect gallbladder disease and perform appropriate diagnostic studies when symptoms arise (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, the label does not provide specific guidance on monitoring frequency or risk stratification for patients predisposed to gallbladder conditions. This may leave some ambiguity for clinicians in managing individual patient risk. Causation considerations for affected patients require careful evaluation. The temporal relationship between Ozempic initiation and gallbladder disease onset is not precisely defined in the evidence, but postmarketing reports suggest that events can occur at various times during treatment. The label does not specify a typical latency period, which complicates attribution. Other risk factors for gallbladder disease, such as obesity, rapid weight loss, female sex, and family history, may confound the association. Patients who develop gallbladder symptoms while on Ozempic should undergo gallbladder studies as recommended (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98). Discontinuation of Ozempic may be considered if gallbladder disease is confirmed, though the label does not mandate this, and clinical judgment is required. The timeline between exposure and documented harm is variable. In clinical trials, cholelithiasis was reported during the study period, which typically spans months to years. Postmarketing data may include cases with shorter or longer latencies. The lack of a defined timeline in the label means that clinicians must rely on individual patient history and symptom progression to assess causality. For patients with pre-existing gallbladder conditions, the risk may be elevated, though the label does not explicitly contraindicate Ozempic in such cases. In summary, Ozempic is associated with an increased risk of acute gallbladder disease, including cholelithiasis and cholecystitis, as documented in its prescribing information. The warning is present but may benefit from more detailed guidance on monitoring and risk management. Patients and healthcare providers should remain vigilant for symptoms of gallbladder disease during Ozempic therapy and pursue appropriate diagnostic evaluation when indicated. References https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166 https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

Does Ozempic cause gallbladder disease?

Yes, Ozempic (semaglutide) is associated with an increased risk of acute gallbladder disease, including cholelithiasis (gallstones) and cholecystitis (inflammation of the gallbladder). This is documented in the drug's prescribing information and postmarketing surveillance data (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

What are the symptoms of gallbladder disease from Ozempic?

Symptoms typically include right upper quadrant abdominal pain, nausea, vomiting, and fever. Diagnosis is confirmed through imaging studies like ultrasound. If gallbladder disease is suspected, the prescribing information advises performing appropriate diagnostic studies (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98).

How common is gallbladder disease with Ozempic?

In placebo-controlled trials for glycemic control, cholelithiasis was reported in 1% of patients treated with semaglutide tablets at a dose of 7 mg once daily (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98). The absolute risk remains low, but the warning is included in the label.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gallbladder Disease diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.